NoneNo Change
All-cause mortality
Intensive glycemic control → All-cause mortality
Intensive glycemic control → All-cause mortality
Evidence profile
NoneNo ChangeClinical Outcomes
Unlock full evidence details
Research Summary
Analyzed using Evidence Intelligence™
Intensive glycemic control may lower cardiovascular events in some diabetes patients
Key finding
Intensive glycemic control was associated with lower MACE in pooled study data.
This study examined the effects of intensive versus standard glycemic control on cardiovascular events in type 2 diabetes patients, finding no significant differences in certain outcomes.
Evidence strength
Moderate confidence
Study type
RCTs
Follow-up
Extended (5–20+ y)
Some Concerns bias
Last updated July 6, 2026Quick read
Study at a glance
The essential study design details in one scan.
Population
Young Adult (19–39), Middle Aged (40-64), Male, Female, Asia-Pacific (APAC), with T2 Diabetes
Intervention
Intensive glycemic control, Standard glycemic control
Study type
RCTs
Follow-up
Extended (5–20+ y)
Primary outcome
Composite cardiovascular events (CV death
Comparator
Standard glycemic control
Plain-language summary
What this paper says
A plain-language read of the study's main message and where it applies.
Study focus
This study examined the effects of intensive versus standard glycemic control on cardiovascular events in type 2 diabetes patients, finding no significant differences in certain outcomes.
Clinical relevance
Understanding the varying effects of glycemic control on cardiovascular outcomes is crucial for tailoring diabetes management strategies. This study highlights the need for personalized treatment approaches, as intensive glycemic control may not benefit all patients equally, potentially guiding clinicians in making informed decisions about diabetes care.
Keep in mind
Effectiveness of interventions was unclear in some cases. Results may not be generalizable to all populations. Subgroup analyses had varying outcomes, complicating interpretations.
Published in
Journal Reference
Publication details and source links for this paper.
Justin AE, Kevin J, Gideon B, et al. Heterogeneous Treatment Effects of Intensive Glycemic Control on Major Adverse Cardiovascular Events in Type 2 Diabetes Patients. Cardiovascular Diabetology. 2022;21:58. doi:10.1186/s12933-022-01496-7
Save this study and add notes to your research library.
Main Effects
Intensive glycemic control was associated with a 4.2% decrease in composite cardiovascular events in pooled data.
No significant difference in composite cardiovascular events was noted in some subgroups.
All-cause mortality rates showed no significant difference between the two treatment groups.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Intensive glycemic control, Standard glycemic control and All-cause mortality, Composite cardiovascular events (CV death, MI, stroke, HF hospitalization).
This study contributes evidence to
Primary intervention
Intensive glycemic control
Primary outcomes
- All-cause mortality
- Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Evidence topics
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
3
Evidence pairs
3
Relationships
1
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 59
1
Related topics
3
Evidence pairs
33
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 3 evidence relationships
- Includes primary outcome data
- Linked to 1 direct semantic evidence topic
Topic contributions
Evidence topic
Contributes evidence
Core evidence
Study findings
The primary outcomes reported in this study.
NoneDecrease
Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Intensive glycemic control → Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Intensive glycemic control → Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Evidence profile
NoneDecreaseClinical Outcomes
Unlock full evidence details
NoneNo Change
Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Standard glycemic control → Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Standard glycemic control → Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Evidence profile
NoneNo ChangeClinical Outcomes
Unlock full evidence details
Unlock full evidence analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Evidence Suggest
- Intensive glycemic control reduced MACE by 4.2% in pooled data.
- No significant differences in MACE were found in certain subgroups.
- All-cause mortality rates were similar between treatment groups.
Who this applies to
- Adults diagnosed with type 2 diabetes.
- Patients undergoing glycemic control treatment.
Keep in Mind
- The study's findings may not apply to all diabetes patients.
- Subgroup differences highlight the need for personalized treatment.
- Unclear effectiveness suggests further research is needed.
Between the Lines
- Effectiveness of interventions was unclear in some cases.
- Results may not be generalizable to all populations.
- Subgroup analyses had varying outcomes, complicating interpretations.
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Already have an account?
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Intensive glycemic control improve all-cause mortality?
Limited Evidence
Current evidence does not show a clear benefit of Intensive glycemic control for All-cause mortality.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
All-cause mortality
EvidenceScore™ Limited | EvidenceScore™ 35.4 | neutral | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Intensive glycemic control improve composite cardiovascular events (cv death, mi, stroke, hf hospitalization)?
Limited Evidence
Current evidence does not show a clear benefit of Intensive glycemic control for Composite cardiovascular events (CV death, MI, stroke, HF hospitalization).
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
EvidenceScore™ Limited | EvidenceScore™ 35.4 | neutral | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Standard glycemic control improve composite cardiovascular events (cv death, mi, stroke, hf hospitalization)?
Limited Evidence
Current evidence does not show a clear benefit of Standard glycemic control for Composite cardiovascular events (CV death, MI, stroke, HF hospitalization).
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
EvidenceScore™ Limited | EvidenceScore™ 35.4 | neutral | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, archive views, and research summaries.
Explore in archive
Open broader archive views for this relationship.
All studies on Intensive glycemic control and Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)All studies on Intensive glycemic control and All-cause mortalityAll studies on Standard glycemic control and Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Related research
Read related research summaries.
Canagliflozin reduces cardiovascular and kidney risks in type 2 diabetesCanagliflozin with metformin reduces cardiovascular risk in T2DMHbA1c mediates cardiovascular benefits of GLP-1 receptor agonistsIntensive multifactorial therapy reduces mortality risk in women with diabetesSGLT2 inhibitors reduce cardiovascular events in diabetes
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.